Karen Rafferty

Christopher Baker, Tianyu Ren, Karen Rafferty et al.

The acceleration of automated scientific discovery has been fundamentally bottlenecked by the epistemic gap between the semantic reasoning of large language models (LLMs) and the deterministic physics of mammalian biology. While recent multi-agent frameworks have achieved autonomous hypothesis generation and in vitro experimental analysis, they lack the mathematically grounded, causal constraints required for multi-scale clinical translation. Furthermore, while algorithmic clinical digital twins successfully forecast biological states, they rely on black-box latent spaces, sacrificing mechanistic interpretability for predictive accuracy. Here, we introduce the Multi-Scale Autonomous Discovery Engine (Octopus), a neuro-symbolic architecture that unites zero-leakage, local LLM swarms with strict algorithmic physics engines. Rather than stopping at isolated cellular assays, the system autonomously generated therapeutic hypotheses against in vitro CRISPR dependency data (CCLE), traced dynamic causal cascades using mechanistic interpretability (XGBoost SHAP vectors), and orthogonally translated the emergent vulnerabilities in silico to predict in vivo mammalian tumor trajectory (PDX) and human overall survival (Marisa). In a fully unsupervised sweep of colorectal cancer transcriptomes, the pipeline autonomously identified Insulin-like Growth Factor 2 (IGF2) as a strictly bounded vulnerability to 5-Fluorouracil resistance. The discovery maintained significance after rigorous Benjamini-Hochberg false discovery rate correction (q=0.0292, Log-Rank p=0.0007 ) and successfully predicted significant in vivo tumor volume shrinkage in an independent mouse cohort (Mann-Whitney p=0.0373). By bridging the chasm between multi-agent reasoning and mathematically bounded clinical survival, this framework establishes a verifiable, zero-leakage paradigm for automated, end-to-end biomedical discovery.

Christopher Baker, Karen Rafferty, Hui Wang

Precision oncology is currently limited by the small-N, large-P paradox, where high-dimensional genomic data is abundant, but high-quality drug response samples are often sparse. While deep learning models achieve high predictive accuracy, they remain black boxes that fail to provide the causal mechanisms required for clinical decision-making. We present a Neuro-Symbolic Agentic Framework that bridges this gap by integrating a quantitative machine learning World Model with an LLM-based agentic reasoning layer. Our system utilises a forensic data pipeline built on the Sanger GDSC dataset (N=83), achieving a robust predictive correlation (r=0.504) and a significant performance gain through the explicit modelling of clinical context, specifically Microsatellite Instability (MSI) status. We introduce the concept of Inverse Reasoning, where the agentic layer performs in silico CRISPR perturbations to predict how specific genomic edits, such as APC or TP53 repair, alter drug sensitivity. By distinguishing between therapeutic opportunity and contextual resistance, and validating these findings against human clinical data (p=0.023), our framework provides a transparent, biologically grounded path towards explainable AI in cancer research.